AUS
NZ
UK
CA
USA
IND
ResMed Inc., a prominent health technology firm, has finalized an agreement to divest its MatrixCare business to Frazier Healthcare Partners for $490 million. This strategic decision supports ResMed's 2030 vision to prioritize high-growth sectors like sleep health and connected home healthcare. The deal is anticipated to close in the first quarter of ResMed's fiscal year 2027, subject to regulatory approvals.
Key Points
- Company and ticker: ResMed Inc. (RMD)
- Major development: MatrixCare business sale for $490 million
- Important dates and milestones: Expected closing in fiscal year 2027 Q1
- Investor focus: Regulatory approval status and strategic impact on ResMed
ResMed's Strategic Realignment Toward High-Growth Sectors
The sale of MatrixCare aligns with ResMed’s long-term strategy to concentrate on scalable opportunities in sleep health, respiratory care, and connected home-based healthcare. This divestiture will enable ResMed to better allocate resources toward innovation and operational scaling. By focusing on these expanding markets, ResMed aims to create sustained value and enhance patient outcomes through its connected care platform.
MatrixCare, which delivers software solutions to over 15,000 providers across skilled nursing, senior living, and long-term care, will be sold to sharpen ResMed’s core market focus. This strategic shift is expected to strengthen ResMed’s leadership in delivering transformative health technologies and generating stakeholder value.
Financial Details of the MatrixCare Divestiture
The $490 million all-cash transaction, subject to closing adjustments, is projected to finalize in ResMed’s fiscal year 2027 first quarter. Proceeds from the sale will be utilized for shareholder returns, including an accelerated share repurchase program, as well as general corporate purposes. This approach underscores ResMed’s dedication to enhancing shareholder value while maintaining strategic priorities.
Preliminary fiscal year 2026 results indicate MatrixCare contributed approximately $220 million in revenue and $55 million in non-GAAP operating profit. While specific future earnings impacts were not disclosed, ResMed confirmed the transaction supports its broader strategic objectives.
Transition Services and Maintaining Operational Stability
To ensure a seamless transition, ResMed and Frazier Healthcare Partners will establish transition services agreements (TSAs) to maintain continuity in systems, processes, tools, and daily operations. These agreements are designed to largely offset stranded costs during the first year after closing. ResMed plans to gradually eliminate any remaining stranded costs, minimizing operational disruptions.
The TSAs demonstrate ResMed’s commitment to operational stability throughout the transition, reassuring stakeholders that core business activities will remain unaffected.
Effect on ResMed's Financial Outlook
ResMed reaffirmed its full-year fiscal 2026 outlook for non-GAAP gross margin, SG&A as a percentage of revenue, R&D as a percentage of revenue, and non-GAAP tax rate. The company also confirmed its fiscal 2026 fourth-quarter outlook for net interest income and planned share repurchases, as previously disclosed in its third-quarter earnings call.
Despite the MatrixCare sale, ResMed expects its Residential Care Software (RCS) segment to achieve high single-digit percentage year-over-year revenue growth and operating leverage in fiscal 2027. The company will provide its full fiscal 2027 outlook during the fourth-quarter fiscal 2026 earnings call on August 6, 2026.
Frazier Healthcare Partners’ Growth Plans for MatrixCare
Frazier Healthcare Partners, a healthcare-focused private equity firm, expressed strong enthusiasm for acquiring MatrixCare. The firm intends to invest substantially in product innovation to support providers in delivering improved outcomes within the evolving post-acute care sector. Frazier’s commitment aligns with MatrixCare’s established leadership serving skilled nursing, senior living, and home health and hospice providers.
Ryan Lucero, General Partner at Frazier Healthcare Partners, emphasized confidence in MatrixCare’s growth potential under new ownership, anticipating continued success in the post-acute care technology market.
ResMed’s Recent Acquisitions and Future Growth Outlook
Alongside the MatrixCare divestiture, ResMed’s acquisition of Noctrix is projected to add around $30 million in revenue and reduce non-GAAP diluted EPS by approximately $0.20 in fiscal 2027. This acquisition highlights ResMed’s strategic emphasis on expanding its sleep and respiratory health technology portfolio.
ResMed remains well-positioned to capitalize on growing demand for connected home healthcare solutions. The MatrixCare divestiture is expected to enhance the company’s capacity for innovation and market expansion in high-growth areas.
Regulatory Approvals and Closing Conditions
The completion of the MatrixCare sale depends on obtaining required regulatory approvals and meeting customary closing conditions. ResMed and Frazier Healthcare Partners are collaborating to facilitate a timely and smooth transaction. Investors will monitor regulatory progress and any effects on the transaction timeline.
While specific regulatory timelines were not provided, the transaction is anticipated to close in the first quarter of ResMed’s fiscal year 2027. This closing will represent a key milestone in ResMed’s strategic repositioning.
Investor Considerations Moving Forward
Investors should watch for updates on regulatory approvals and the finalization of the MatrixCare sale. Additionally, ResMed’s fourth-quarter fiscal 2026 earnings call on August 6, 2026, will offer further clarity on the company’s financial outlook and strategic direction for fiscal 2027.
As ResMed intensifies its focus on high-growth markets, investors will evaluate the long-term impact of the MatrixCare divestiture on growth prospects and value creation through innovation and operational excellence.
